High expression of PD-L1 in NSCLC is a predictive factor of the therapeutic effectiveness of pembrolizumab on primary lung lesions (33, 34), however, there are no reports regarding the effect on bone metastases. The gene discussed is CD274; the disease is non-small cell lung carcinoma.